Baudax Bio is a specialty pharmaceutical company focused on developing and commercializing innovative products for acute care settings.
Baudax Bio has raised $1.9M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in August 2023.
Baudax Bio's investors include Marathon Asset Management.
Baudax Bio is headquartered in Malvern, United States.
Baudax Bio is a specialty pharmaceutical company focused on developing and commercializing innovative products for acute care settings.
Baudax Bio is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Baudax Bio — Funding & Investors." VCBacked, August 17, 2023, https://www.vcbacked.co/company/baudax-bio. Accessed August 14, 2026.
VCBacked. (2023). Baudax Bio — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/baudax-bio
{{cite web |title=Baudax Bio — Funding & Investors |url=https://www.vcbacked.co/company/baudax-bio |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated